GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2007

Axxam and Boehringer Ink Two Drug Research Agreements

  • Axxam signed two drug research collaboration agreements with Boehringer Ingelheim. The first collaboration agreement aims to identify and validate therapeutic targets with subsequent assay development, high-throughput screening (HTS), and lead optimizations.

    The second agreement covers the transfer of protein material and a corresponding specific functional assay for HTS to Boehringer Ingelheim.

    Axxam will receive fees as the collaboration progresses and milestone payments for successful exploitation of results through development stages.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?